

ERBB2

Human anti-ERBB2 / HER2 (Trastuzumab emtansine) mAb

Catalog No.	CSB111A	Quantity:	200 µg
	CSB111B		1.0 mg
Alternate Names:	PRO132365, RG3502, T-DM1, trastuzumab-MCC-DM1, Kadcyla		
Description:	Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.		
Concentration:	1.0 mg/ml		
UniProt ID (target):	P04626		
Source:	CHO cell line		
Isotype:	Human IgG1 kappa		
INN:	Trastuzumab emtansine		
Specificity:	Human Receptor tyrosine-protein kinase erbB-2 (ERBB2)		
Biologic Activity:	Binding to HER2 receptor		
Formulation:	PBS, pH 7.5		
Purity:	> 95% as determined by SDS-PAGE		
Reactivity:	Human		
Applications:	Functional studies, ELISA		
Storage & Stability:	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

